EL7.AI
StocksMediumUpdated×2•Originally published 23 March 2026•Updated 23 March 2026•
1 min read

Musk’s Trillion-Dollar ‘Terafab’ Chip Plan Sparks Investor Concerns Over Tesla’s Capital

Key Facts

1Elon Musk is planning 'Terafab,' a joint venture between SpaceX and Tesla.
2Analysts estimate the cost of this massive venture could reach trillions of dollars.
3The plan raises questions about investor faith in Musk's ability to fund and execute projects of this scale.

Elon Musk’s ambitious 'Terafab' project, a semiconductor joint venture between Tesla and SpaceX, continues to stir market debate over its potential trillion-dollar price tag. While the plan aims for vertical integration, analysts warn that the massive capital expenditure (CAPEX) requirements could lead to significant share dilution for investors. Interestingly, the initiative has identified chip-equipment manufacturers as potential beneficiaries of this massive internal manufacturing push. Despite the grand scale, many market experts characterize the venture as being heavy on hype while currently lacking specific technical or operational details. This lack of transparency, combined with the unprecedented cost, is testing investor faith in Musk’s capital allocation strategy. Consequently, the long-term valuation of Tesla remains under pressure as the market awaits more concrete plans regarding the project's execution.